Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

July 8, 2019

Study Completion Date

January 1, 2021

Conditions

Chronic Kidney Disease

Interventions

DRUG

D6-25-hydroxyvitamin D3

Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3

Trial Locations (1)

University of Washington, Seattle

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Washington

OTHER

NCT03576716 - Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation | Biotech Hunter | Biotech Hunter